Earnings Call Summary | Aadi Biosciences(AADI.US) Q4 2023 Earnings Conference
Earnings Call Summary | Aadi Biosciences(AADI.US) Q4 2023 Earnings Conference
The following is a summary of the Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript:
以下是亞迪生物科學公司（AADI）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Aadi Bioscience reported impressive sales growth with full-year sales for FYARRO hitting $24.4 million, an upward trend of 60% from the previous year.
Quarter 4 FYARRO net product sales amounted to $6.3 million, marking a 6% climb from the preceding quarter, and a 21% surge YoY.
As research and development activities intensified, expenses escalated to $12.8 million for the quarter, compared to $9.4 million in the same quarter of the preceding year.
A decrease was recorded in Selling, general and administrative expenses in the fourth quarter year-on-year; $10.3 million in 2023 compared to $11.1 million in 2022.
Net loss for Q4 broadened to $16.3 million up from a net loss of $13.9 million in Q4 2022.
The company ended 2023 with a robust bullish position with $108.8 million in cash, equivalents, and short-term investments.
Aadi Bioscience報告了令人印象深刻的銷售增長，FYARRO的全年銷售額達到2440萬美元，比上年增長了60％。
FYARRO第四季度產品淨銷售額爲630萬美元，比上一季度增長6％，同比增長21％。
隨着研發活動的加強，本季度的支出激增至1,280萬美元，而去年同期爲940萬美元。
第四季度的銷售、一般和管理費用同比下降；2023年爲1,030萬美元，而2022年爲1,110萬美元。
第四季度的淨虧損從2022年第四季度的1,390萬美元淨虧損擴大至1,630萬美元。
該公司在2023年底保持強勁的看漲地位，擁有1.088億美元的現金、等價物和短期投資。
Business Progress:
業務進展：
AADI Bioscience demonstrated robust progress in 2023, exploring the potential of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations.
Preliminary results from the ongoing PRECISION 1 trial indicate early and sustained reductions in tumor sizes across four different tumor types.
The onboarding process for the PRECISION 1 trial is forecasted to complete by May 2024, with interim and full trial data ready for analysis in Q3 2024, and early 2025 respectively.
Ambitious pursuits continue with the commencement of two Phase II single indication trials on two promising mTOR driven cancer targets.
In pursuit of its multifold precision oncology objectives, the company implemented measures to streamline operations and cut costs, ensuring financial sustainability up to Q4 2025.
Aadi Bioscience launched a Phase II study to investigate the combination of nab-sirolimus with letrozole in patients with advanced or unresectable Stage 3 or 4 or recurrent endometrioid endometrial carcinoma, with early results anticipated by the year-end.
AADI Bioscience在2023年取得了長足的進展，探索了nab-sirolimus在含有TSC1或TSC2失活變異的實體瘤患者中的潛力。
正在進行的PRECISION 1試驗的初步結果表明，四種不同腫瘤類型的腫瘤大小會盡早持續減小。
預計PRECISION 1試驗的入職流程將在2024年5月之前完成，中期和完整的試驗數據將分別在2024年第三季度以及2025年初準備好進行分析。
隨着針對兩個有前景的mTOR驅動的癌症靶標的兩項II期單一適應症試驗的開始，雄心勃勃的追求仍在繼續。
爲了實現其多重精準腫瘤學目標，該公司採取了簡化運營和削減成本的措施，確保了2025年第四季度的財務可持續性。
Aadi Bioscience啓動了一項II期研究，以調查nab-sirolimus與來曲唑聯合治療晚期或不可切除的3期或4期或複發性子宮內膜癌患者的情況，預計將在年底前取得初步結果。
More details: Aadi Biosciences IR
更多詳情： Aadi Biosciences
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。